The tumor promoter 12-O-tetradecanoylphorbol-13-acetate and the antileukemic agent mezerein are diterpene esters of plant origin with certain structural similarities. Both compounds, when applied topically to mouse skin, were equipotent on a molar basis in inducing hyperplasia, inflammation, and ornithine decarboxylase activity, as well as in reducing cyclic adenosine 3′:5′-monophosphate accumulation in response to β-adrenergic stimulation. In contrast, mezerein was much less effective as a tumor promoter; the phorbol ester at 8.5 nmol/application yielded 78-fold more tumors than did 8.5 nmol mezerein per application to similarly initiated SENCAR mice. The superiority of the phorbol ester was nearly as great in CD-1 mice.

These results suggest that although the induction of hyperplasia and ornithine decarboxylase activity may be necessary components of the carcinogenic process, they are not sufficient; 12-O-tetradecanoylphorbol-13-acetate must accomplish an essential event not accomplished by mezerein.

1

Research jointly sponsored by the NIH under Grant CA 07175; the National Cancer Institute under Contract YO1CP70227; and the Office of Health and Environmental Research, United States Department of Energy, under Contract W-7405-eng-26 with the Union Carbide Corporation.

This content is only available via PDF.